Biogen Idec’s ALS drug Failed Final Clinical Trial

.

Biogen Idec’s ALS drug Failed Final Clinical Trial

As per reports, it has been recently revealed that Biogen Idec was unable to get through the last clinical trial of its ALS drug. Researchers have acknowledged the loss by saying that it was not only shocking but discouraging as well.

Dr. Robert Brown, who is an ALS researcher, was of the view that they have worked hard on the drug, but they failed a crucial test. However, this does not mean that no more research will take as the disease needs an effective treatment.

While talking about the last and final clinical trial, which could not attain success, Brown said that they had enrolled 943 people, who were suffering from amyotrophic lateral sclerosis. They were enrolled to test the efficacy of their once-promising dexpramipexole drug.

After carrying out the study, Brown said that they did not find any sort of benefit from the drug. And, then only, they decided to halt the programme. "While these results were not what we expected, we hope this data will provide a foundation for future ALS research", said Dr. Douglas Kerr, who is the director of neurodegeneration clinical research at Biogen.

The failure does not mark an end to the research, said Kerr, as they still have been working on it.

 


Latest News

South Korean Automaker Kia to Construct a $1 Billion Car Assembly Plant In Mexic
Deal Reached Finally for Market Basket: Ex CEO to Buy the Supermarket Chain
Latest Funding Value Snapchat at $10 billion
American Airlines Pulls Listing and Fares from Orbitz Due to Unsuccessful Effort
Is Burger King’s Deal with Tim Hortons Going to Affect Its Popularity?
Fans Show Twitch’s $970 Million Acquisition is Worth It
Ann Taylor (ANN) Shares Increase as Activist and Investors Put Pressure for Sale
Though The Market Basket Employees are Disappointed But They are not Giving up P
CME Group Faces Technical Glitch that Halts Trading for Four Hours
Survey Shows Lesser Number of Economists Believe US Monetary Policy to be on Rig
Burger King in Discussion with Canada's Tim Hortons for a Merger
Ackman and Valeant call for special meeting of Allergan shareholders